These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27022633)

  • 21. Statistics Commentary Series. Commentary No. 42: Minimization.
    Streiner DL
    J Clin Psychopharmacol; 2020; 40(5):441-442. PubMed ID: 32701908
    [No Abstract]   [Full Text] [Related]  

  • 22. Lies, damn lies, and statistics.
    Yentis SM
    Anaesthesia; 2012 May; 67(5):455-456. PubMed ID: 22404377
    [No Abstract]   [Full Text] [Related]  

  • 23. Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates.
    Zimmermann G; Kieser M; Bathke AC
    J Biopharm Stat; 2020; 30(1):143-159. PubMed ID: 31327284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.
    Shrier I
    Stat Med; 2008 Jun; 27(14):2740-1; author reply 2741-2. PubMed ID: 18069729
    [No Abstract]   [Full Text] [Related]  

  • 25. Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies.
    Wang X; Ji X
    Chest; 2020 Jul; 158(1S):S12-S20. PubMed ID: 32658647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Propensity Score Analysis a Valid Surrogate of Randomization for the Avoidance of Allocation Bias?
    Torres F; Ríos J; Saez-Peñataro J; Pontes C
    Semin Liver Dis; 2017 Aug; 37(3):275-286. PubMed ID: 28847037
    [No Abstract]   [Full Text] [Related]  

  • 27. Design and interpretation of equivalence trials.
    Fleming TR
    Am Heart J; 2000 Apr; 139(4):S171-6. PubMed ID: 10740126
    [No Abstract]   [Full Text] [Related]  

  • 28. Alternatives to Randomised Controlled Trials for the Poor, the Impatient, and When Evaluating Emerging Technologies.
    Mani K; Björck M
    Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):598-599. PubMed ID: 30509892
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect size in CASTLE-AF trial: the issue of 'the tiny effect'.
    Sierra F; Gomez Gomez D; Londoño Mora J
    BMJ Evid Based Med; 2018 Dec; 23(6):239. PubMed ID: 30054372
    [No Abstract]   [Full Text] [Related]  

  • 30. Missing data in rheumatologic studies and the practical reality of modern approaches to the analysis of incomplete subject data: comment on the article by Baron et al and the editorial by Boers.
    Steele R; Hudson M
    Arthritis Rheum; 2008 Sep; 59(9):1367-8. PubMed ID: 18759312
    [No Abstract]   [Full Text] [Related]  

  • 31. Undue reliance on I(2) in assessing heterogeneity may mislead.
    Rücker G; Schwarzer G; Carpenter JR; Schumacher M
    BMC Med Res Methodol; 2008 Nov; 8():79. PubMed ID: 19036172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes.
    Dodd S; White IR; Williamson P
    Trials; 2017 Oct; 18(1):498. PubMed ID: 29070048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Putting the record straight: granisetron's efficacy as an antiemetic 'post-Fujii'.
    Kranke P
    Anaesthesia; 2012 Oct; 67(10):1063-7. PubMed ID: 22897144
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis and reporting of stepped wedge randomised controlled trials: synthesis and critical appraisal of published studies, 2010 to 2014.
    Davey C; Hargreaves J; Thompson JA; Copas AJ; Beard E; Lewis JJ; Fielding KL
    Trials; 2015 Aug; 16():358. PubMed ID: 26278667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 37. An imbalance in cluster sizes does not lead to notable loss of power in cross-sectional, stepped-wedge cluster randomised trials with a continuous outcome.
    Kristunas CA; Smith KL; Gray LJ
    Trials; 2017 Mar; 18(1):109. PubMed ID: 28270224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ignoring the group in group-level HIV/AIDS intervention trials: a review of reported design and analytic methods.
    Pals SL; Wiegand RE; Murray DM
    AIDS; 2011 Apr; 25(7):989-96. PubMed ID: 21487252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Confirmatory clinical trials with an adaptive design.
    Koch A
    Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reporting of sample-size calculations for randomized trials in dermatology: comparison of publications with registries.
    Weinberg T; Wang G; Lam K; Kitchen J; Chan AW
    Br J Dermatol; 2019 Apr; 180(4):929-930. PubMed ID: 30339744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.